Microvascular endothelial dysfunction in heart failure with preserved ejection fraction

Heart

Volumn 102, Issue 4, 2016, Pages 257-259

  Lam, Carolyn S P ^a   Lund, Lars H ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY BLOOD FLOW; BRACHIAL ARTERY; CAPILLARY ENDOTHELIUM; CLINICAL FEATURE; COMORBIDITY; CORONARY FLOW RESERVE; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE PERFUSION; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; SHEAR STRESS; VASODILATATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; VASCULAR DISEASE;

HEART FAILURE; HUMANS; STROKE VOLUME; VASCULAR DISEASES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84959368307     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308852     Document Type: Editorial

References (20)

1. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
2. Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: Current state and future directions. JACC Heart Fail 2014; 2: 97-112.
3. Brutsaert DL, Meulemans AL, Sipido KR, et al. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 1988; 62: 358-66.
4. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation 1995; 92: 2119-26.
5. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56: 845-54.
6. Matsue Y, Suzuki M, Nagahori W, et al. Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 2013; 168: 36-40.
7. Akiyama E, Sugiyama S, Matsuzawa Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2012; 60: 1778-86.
8. Farrero M, Blanco I, Batlle M, et al. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 791-8.
9. Haykowsky MJ, Herrington DM, Brubaker PH, et al. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci 2013; 68: 161-7.
10. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-To-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
11. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011; 4: 44-52.
12. Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131: 550-9.
13. Kitzman DW, Nicklas B, Kraus WE, et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 2014; 306: H1364-70.
14. Lam CS, Brutsaert DL. Endothelial dysfunction: A pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol 2012; 60: 1787-9.
15. Lim SL, Lam CS, Segers VF, et al. Cardiac endothelium-myocyte interaction: Clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J 2015; 36: 2050-60.
16. Lee JF, Barrett-O'Keefe Z, Garten RS, et al. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart 2016; 102: 278-84.
17. Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: The Framingham Heart Study. Hypertension 2004; 44: 134-9.
18. Philpott AC, Lonn E, Title LM, et al. Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. Am J Cardiol 2009; 103: 1610-15.
19. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300: H2-12.
20. Atkinson G, Batterham AM, Black MA, et al. Is the ratio of flow-mediated dilation and shear rate a statistically sound approach to normalization in cross-sectional studies on endothelial function? J Appl Physiol 2009; 107: 1893-9.